Aim: : There is a lack of literature on the imaging of neuroendocrine tumours in children so much so as imaging findings have been derived from adult studies. The aim of this study was to evaluate the use of 99mTechnetium-Hydrazinonicotinyl-Tyr3-Octreotide (99mTc HYNIC TOC) for diagnosing and staging neuroendocrine tumours in children with special emphasis on the acquisition protocol including Single Photon Emission Computed Tomography (SPECT) co-registration with Computed Tomography (CT).　　Method: 22 patients (15 boys, 7 girls;Age Range:46 days-9 years;Mean age=2.08 years) underwent 99mTc-HYNIC-TOC whole body scintigraphy (early and late stage) and regional SPECT/CT post intravenous injection of 10mCi of the radiopharmaceutical. Images were evaluated both qualitatively and semi-quantitatively by two experienced nuclear medicine physicians and results compared with those of conventional imaging. Histopathology results and conventional imaging with biochemical markers were considered as reference standards.　　Results: Whole body planar scans and SPECT/CT imaging were found to be superior to conventional imaging modalities for detection of primary tumours and metastases with a sensitivity of 82.4%, specificity of 80%and accuracy of 81.8%. Neuroblastomas were the most common neuroendocrine tumour diagnosed (77.3%).　　Conclusion: 99mTc HYNIC TOC imaging appears to be highly useful in improving detection of neuroendocrine tumours and metastases in children. It can significantly impact on patient management and further treatment options. Neuroendocrine tumours can be comprehensively diagnosed in children with the above one day, dual time protocol.